-
Mashup Score: 24
Early data on a new blood test, which looks for bits of RNA discharged by tumors, suggests it might be able to detect pancreatic cancer at stage 1 or 2 with a sensitivity of over 90%.
Source: www.statnews.comCategories: General Medicine News, General HCPsTweet
-
Mashup Score: 24
Early data on a new blood test, which looks for bits of RNA discharged by tumors, suggests it might be able to detect pancreatic cancer at stage 1 or 2 with a sensitivity of over 90%.
Source: www.statnews.comCategories: General Medicine News, General HCPsTweet-
Early data from a new liquid biopsy screening test suggests that it might be able to detect pancreatic cancer at stage 1 or 2 with a sensitivity of over 90%. #AACR https://t.co/Yu1AiEtfZE
-
-
Mashup Score: 10The latest updates on cancer research from the weekend - 17 day(s) ago
Cancer is becoming increasingly prevalent among younger people. New evidence presented at AACR suggests why that may be the case
Source: www.statnews.comCategories: General Medicine News, General NewsTweet-
Cancer is becoming increasingly prevalent among younger people. New evidence presented at #AACR suggests why that may be the case https://t.co/JrH3qUAara
-
-
Mashup Score: 1Targeting SORT1-Positive Cancers - 8 month(s) ago
Dr. Christian Marsolais discusses three studies recently presented at the AACR conference targeting SORT1-positive cancers.
Source: CheckRare.comCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
Christian Marsolais, Ph.D., Chief Medical Officer of Theratechnologies, discusses three studies presented at the American Association for Cancer Research #AACR conference targeting SORT1-positive cancers #checkrare #rarediseases @AACR @Theratech_ https://t.co/RuKuGtSP0n
-
-
Mashup Score: 1Targeting SORT1-Positive Cancers - 9 month(s) ago
Dr. Christian Marsolais discusses three studies recently presented at the AACR conference targeting SORT1-positive cancers.
Source: CheckRareCategories: Latest Headlines, Rare DiseaseTweet-
Christian Marsolais, Ph.D., Chief Medical Officer of Theratechnologies, discusses three studies presented at the American Association for Cancer Research #AACR conference targeting SORT1-positive cancers #checkrare #rarediseases @AACR @Theratech_ https://t.co/RuKuGtSP0n
-
-
Mashup Score: 0Targeting SORT1-Positive Cancers - 10 month(s) ago
Dr. Christian Marsolais discusses three studies recently presented at the AACR conference targeting SORT1-positive cancers.
Source: CheckRareCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
Christian Marsolais, Ph.D., Chief Medical Officer of Theratechnologies, discusses three studies presented at the American Association for Cancer Research #AACR conference targeting SORT1-positive cancers #checkrare #rarediseases @AACR @Theratech_ https://t.co/RuKuGtSP0n
-
-
Mashup Score: 1Targeting SORT1-Positive Cancers - 11 month(s) ago
Dr. Christian Marsolais discusses three studies recently presented at the AACR conference targeting SORT1-positive cancers.
Source: CheckRareCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
Christian Marsolais, Ph.D., Chief Medical Officer of Theratechnologies, discusses three studies presented at the American Association for Cancer Research #AACR conference targeting SORT1-positive cancers #checkrare #rarediseases @AACR @Theratech_ https://t.co/RuKuGtSP0n
-
-
Mashup Score: 0Targeting SORT1-Positive Cancers - 11 month(s) ago
Dr. Christian Marsolais discusses three studies recently presented at the AACR conference targeting SORT1-positive cancers.
Source: CheckRareCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
Christian Marsolais, Ph.D., Chief Medical Officer of Theratechnologies, discusses three studies presented at the American Association for Cancer Research #AACR conference targeting SORT1-positive cancers #checkrare #rarediseases @AACR @Theratech_ https://t.co/RuKuGtSP0n
-
-
Mashup Score: 4Pembrolizumab in Addition to Cisplatin and Gemcitabine Boosts Overall Survival in Advanced Biliary Tract Cancer - 1 year(s) ago
Patients who received pembrolizumab plus cisplatin and gemcitabine achieved a median overall survival of 12.7 months, compared with 10.9 months with cisplatin and gemcitabine alone.
Source: Oncology Nursing NewsCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
Patients who received pembrolizumab plus cisplatin and gemcitabine achieved a median overall survival of 12.7 months, compared with 10.9 months with cisplatin and gemcitabine alone. #oncology #nursing #AACR @AACR @UCSFCancer https://t.co/f9RYaWxAVJ https://t.co/Wa162SSPSF
-
-
Mashup Score: 0AI predicts endometrial cancer recurrence - 1 year(s) ago
Model uses only digitized histopathology slides, but more validation in other populations is needed.
Source: www.mdedge.comCategories: Hem/Oncs, Latest HeadlinesTweet-
#AI predicts #EndometrialCancer recurrence 👉https://t.co/CRJrQJdezy @MDedgeHemOnc @JimKling #AACR https://t.co/OfFRKNWpDO
-
Early data from a new liquid biopsy screening test suggests that it might be able to detect pancreatic cancer at stage 1 or 2 with a sensitivity of over 90%. #AACR https://t.co/Yu1AiEtfZE